Results 181 to 190 of about 377,160 (316)

Development and Immune Efficacy Evaluation of Two Live Triple-Gene-Deleted Vaccine Candidates Against Bovine Herpesvirus Type 1. [PDF]

Animals (Basel)
Gu Y, Duan H, Ji C, Lin H, Lai Y, Zhang J, Zhang C, Huo S, Ni Z, Yun T, Ye W, Hua J, Chen L, Fu Y, Zhu Y, Pan Z.   +15 more
europepmc   +1 more source

Noninvasive Focal Gene Delivery into the Cerebellum of Non‐Human Primates using Focused Ultrasound

Advanced Science, EarlyView.
Focal and non‐invasive viral vector delivery in non‐human primates remains a major challenge in translational neuroscience. Low‐intensity focused ultrasound was used to transiently open the blood–brain barrier and enable targeted gene delivery to the cerebellum.
Noelia Esteban‐García, José A. Pineda‐Pardo, Inés Trigo‐Damas, Marta Gutiérrez, Marta Castillo‐Ortiz, Megan Carrillo, Alejandro Reinares‐Sebastian, Víctor Medina‐Chavarrías, Itay Rachmilevitch, Masahiko Takada, José A. Obeso, Javier Blesa   +11 more
wiley   +1 more source

Oncolytic Viruses for Cancer Therapy in Dogs. [PDF]

Viruses
Neymysheva DO, Ilyinskaya GV, Sarkisova VA, Mukhina EA, Romanen-Kova SA, Chumakov PM.   +5 more
europepmc   +1 more source

Interim guidance for protecting workers from occupational exposure to Zika virus [PDF]

The Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH) are monitoring the impact of the Zika virus on U.S. states and territories, Central and South America, Mexico, and parts of the

core  

Rational Design of Broad‐Spectrum Anti‐Enteroviral Molecular Glues Targeting Enteroviral RNAi Suppressors

Advanced Science, EarlyView.
By leveraging this homodimerization mechanism, molecular glues were rationally designed to induce dysfunctional 3A dimerization, thereby restoring antiviral RNAi. The optimal molecular glue, VTP‐32, demonstrated potent and pan‐enterovirus (groups A, B, D) antiviral effects.
Yuan Fang, Xiong Xie, Huidi Fan, Botao Wu, An Wang, Wenhao Dai, Zezhong Liu, Jian Li, Huoyan Tong, Jianan Li, Yujie Ren, Jinlin Wang, Xi Zhou, Hong Liu   +13 more
wiley   +1 more source

Corrigendum to"A noval strategy of deletion in PK gene for construction of a vaccine candidate with exellent safety and complete protection efficiency against high virulent Chinese pseudorabies virus variant" [Virus Research 313 (2022) 198740]. [PDF]

Virus Res
Xu M, Zhang C, Liu Y, Chen S, Zheng Y, Wang Z, Cao R, Wang J.   +7 more
europepmc   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, EarlyView.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

Age-Related Immune Responses and Long-Term Immunity in Adult Sheep and Goats Following Vaccination with the Nigeria 75/1 Live Attenuated PPR Vaccine. [PDF]

Vet Sci
Bulatov Y, Ussembay A, Amanova Z, Sametova Z, Kondibayeva Z, Abitayev R, Turyskeldi S, Zhugunissov K, Koshemetov Z, Kerimbayev A, Njeumi F, Toktyrova D.   +11 more
europepmc   +1 more source

A Biomimetic Nanoparticle System Intercepts and Degrades Thrombospondin‐1 to Restore Vascular Homeostasis After Ischemic Injury

Advanced Science, EarlyView.
TAX2‐NPs capture extracellular TSP‐1 in the injured liver and promote its macrophage‐mediated autophagic degradation. This process blocks TSP‐1/CD47 signaling, restores VEGFR2‐AKT activity, preserves endothelial function, and mitigates hepatic ischemia‐reperfusion injury.
Haorui Wang, Xiandi Meng, Yanbao Xin, Kuirong Mao, Huizhu Tan, Changkai Ma, Xiuxiu Cong, Mengfei Zhao, Meiling Yu, Si Chen, Yue Hou, Yong‐Guang Yang, Tianmeng Sun   +12 more
wiley   +1 more source

Safety and Immunogenicity of a Vaccine Against Coxsackieviruses B (PRV-101)-Follow-up of the First-in-Human Phase 1 Trial. [PDF]

Open Forum Infect Dis
Laiho JE, Lehtonen JP, Puustinen L, Kääriäinen S, Härkönen T, Oikarinen S, León F, Sanjuan M, Scheinin M, Knip M, Hyöty H.   +10 more
europepmc   +1 more source